Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial

Abstract Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for refractory recurrent/metastatic nasopharyngeal carcinoma (RM-NPC). We conducted a phase 2 trial to evaluate the safety and activity of ca...

Full description

Bibliographic Details
Main Authors: Li Yuan, Guo-Dong Jia, Xiao-Fei Lv, Si-Yi Xie, Shan-Shan Guo, Da-Feng Lin, Li-Ting Liu, Dong-Hua Luo, Yi-Fu Li, Shen-Wen Deng, Ling Guo, Mu-Sheng Zeng, Xiu-Yu Cai, Sai-Lan Liu, Xue-Song Sun, Xiao-Yun Li, Su-Chen Li, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40402-x

Internet

https://doi.org/10.1038/s41467-023-40402-x

Similar Items